These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 9743170)

  • 1. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
    Greidinger EL; Flaherty KT; White B; Rosen A; Wigley FM; Wise RA
    Chest; 1998 Sep; 114(3):801-7. PubMed ID: 9743170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.
    Gelber AC; Manno RL; Shah AA; Woods A; Le EN; Boin F; Hummers LK; Wigley FM
    Medicine (Baltimore); 2013 Jul; 92(4):191-205. PubMed ID: 23793108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gender and ethnicity differences in the prevalence of scleroderma-related autoantibodies.
    Krzyszczak ME; Li Y; Ross SJ; Ceribelli A; Chan EK; Bubb MR; Sobel ES; Reeves WH; Satoh M
    Clin Rheumatol; 2011 Oct; 30(10):1333-9. PubMed ID: 21523365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary involvement in systemic sclerosis: associations with genetic, serologic, sociodemographic, and behavioral factors.
    McNearney TA; Reveille JD; Fischbach M; Friedman AW; Lisse JR; Goel N; Tan FK; Zhou X; Ahn C; Feghali-Bostwick CA; Fritzler M; Arnett FC; Mayes MD
    Arthritis Rheum; 2007 Mar; 57(2):318-26. PubMed ID: 17330281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
    Satoh M; Kuwana M; Ogasawara T; Ajmani AK; Langdon JJ; Kimpel D; Wang J; Reeves WH
    J Immunol; 1994 Dec; 153(12):5838-48. PubMed ID: 7989779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequent coexistence of anti-topoisomerase I and anti-U1RNP autoantibodies in African American patients associated with mild skin involvement: a retrospective clinical study.
    Satoh M; Krzyszczak ME; Li Y; Ceribelli A; Ross SJ; Chan EK; Segal MS; Bubb MR; Sobel ES; Reeves WH
    Arthritis Res Ther; 2011 May; 13(3):R73. PubMed ID: 21569292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world experience of tocilizumab in systemic sclerosis: potential benefit on lung function for anti-topoisomerase-positive patients.
    Suleman Y; Clark KEN; Cole AR; Ong VH; Denton CP
    Rheumatology (Oxford); 2021 Aug; 60(8):3945-3946. PubMed ID: 33734322
    [No Abstract]   [Full Text] [Related]  

  • 9. Scleroderma lung: initial forced vital capacity as predictor of pulmonary function decline.
    Plastiras SC; Karadimitrakis SP; Ziakas PD; Vlachoyiannopoulos PG; Moutsopoulos HM; Tzelepis GE
    Arthritis Rheum; 2006 Aug; 55(4):598-602. PubMed ID: 16874782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interrelationships between pulmonary and extrapulmonary involvement in systemic sclerosis. A longitudinal analysis.
    Tashkin DP; Clements PJ; Wright RS; Gong H; Simmons MS; Lachenbruch PA; Furst DE
    Chest; 1994 Feb; 105(2):489-95. PubMed ID: 8306752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Esophageal hypomotility in systemic sclerosis: close relationship with pulmonary involvement.
    Kinuya K; Nakajima K; Kinuya S; Michigishi T; Tonami N; Takehara K
    Ann Nucl Med; 2001 Apr; 15(2):97-101. PubMed ID: 11448082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody.
    Kuwana M; Kaburaki J; Arnett FC; Howard RF; Medsger TA; Wright TM
    Arthritis Rheum; 1999 Mar; 42(3):465-74. PubMed ID: 10088769
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe restrictive lung disease in systemic sclerosis.
    Steen VD; Conte C; Owens GR; Medsger TA
    Arthritis Rheum; 1994 Sep; 37(9):1283-9. PubMed ID: 7945490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and serological features of systemic sclerosis in a multicenter African American cohort: Analysis of the genome research in African American scleroderma patients clinical database.
    Morgan ND; Shah AA; Mayes MD; Domsic RT; Medsger TA; Steen VD; Varga J; Carns M; Ramos PS; Silver RM; Schiopu E; Khanna D; Hsu V; Gordon JK; Gladue H; Saketkoo LA; Criswell LA; Derk CT; Trojanowski MA; Shanmugam VK; Chung L; Valenzuela A; Jan R; Goldberg A; Remmers EF; Kastner DL; Wigley FM; Gourh P; Boin F
    Medicine (Baltimore); 2017 Dec; 96(51):e8980. PubMed ID: 29390428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lung function decline over 25 years of follow-up among black and white adults in the ARIC study cohort.
    Mirabelli MC; Preisser JS; Loehr LR; Agarwal SK; Barr RG; Couper DJ; Hankinson JL; Hyun N; Folsom AR; London SJ
    Respir Med; 2016 Apr; 113():57-64. PubMed ID: 26905512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased Morbidity and Mortality of Scleroderma in African Americans Compared to Non-African Americans.
    Moore DF; Kramer E; Eltaraboulsi R; Steen VD
    Arthritis Care Res (Hoboken); 2019 Sep; 71(9):1154-1163. PubMed ID: 30821906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis.
    Steen V; Domsic RT; Lucas M; Fertig N; Medsger TA
    Arthritis Rheum; 2012 Sep; 64(9):2986-94. PubMed ID: 22576620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies.
    Shah AA; Rosen A; Hummers L; Wigley F; Casciola-Rosen L
    Arthritis Rheum; 2010 Sep; 62(9):2787-95. PubMed ID: 20506513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to topoisomerase I in sera from patients with scleroderma.
    Shero JH; Bordwell B; Rothfield NF; Earnshaw WC
    J Rheumatol Suppl; 1987 Jun; 14 Suppl 13():138-40. PubMed ID: 3039129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.